{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:15:08Z","timestamp":1787022908475,"version":"build-2736575974"},"reference-count":46,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,1]]},"abstract":"<jats:p>The current epidemic of opioid addiction has arguably been the most recalcitrant in the nation\u2019s history and the first to involve substantial numbers of adolescents. The country has embarked on a public health response, including increasing access to addiction treatment. However, the treatment infrastructure, which was initially created in the 1970s, is ill equipped for meeting the needs of adolescents and young adults, who are often cared for in pediatric primary care. In this article, I review the development of the current treatment system, examine shortfalls in regard to youth-specific needs, and propose suggestions for addressing the current crisis while simultaneously preparing to address future epidemics of addiction by enabling pediatricians to better manage substance use disorders in primary care.<\/jats:p>","DOI":"10.1542\/peds.2018-2752","type":"journal-article","created":{"date-parts":[[2019,1,2]],"date-time":"2019-01-02T13:55:16Z","timestamp":1546437316000},"source":"Crossref","is-referenced-by-count":71,"title":["Youth and the Opioid Epidemic"],"prefix":"10.1542","volume":"143","author":[{"given":"Sharon","family":"Levy","sequence":"first","affiliation":[{"name":"Adolescent Substance Use and Addiction Program, Division of Developmental Medicine, Boston Children\u2019s Hospital, Boston, Massachusetts; and Department of Pediatrics, Harvard Medical School, Harvard University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2019,2,1]]},"reference":[{"key":"2021121021282400600_B1","unstructured":"Trickey\u2008E. Inside the story of America\u2019s 19th-century opiate addiction. Smithsonian Magazine. January 4, 2018. Available at: https:\/\/www.smithsonianmag.com\/history\/inside-story-americas-19th-century-opiate-addiction-180967673\/. Accessed August 13, 2018"},{"key":"2021121021282400600_B2","unstructured":"US Department of Health and Human Services. HHS acting secretary declares public health emergency to address national opioid crisis. 2017. Available at: https:\/\/www.hhs.gov\/about\/news\/2017\/10\/26\/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html. Accessed February 20, 2018"},{"key":"2021121021282400600_B3","unstructured":"Substance Abuse and Mental Health Services Administration. Medication-assisted treatment for opioid addiction in opioid treatment programs. TIP 43. 2005. Available at: https:\/\/www.ohsu.edu\/xd\/health\/for-healthcare-professionals\/telemedicine-network\/for-healthcare-providers\/ohsu-echo\/addiction-medicine\/upload\/Medication-Assisted-Treatment-for-Opioid-Addiction.pdf. Accessed December 6, 2018"},{"issue":"3","key":"2021121021282400600_B4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1067\/mjd.2000.107479","article-title":"Nineteenth-century patent medicines for the skin and hair.","volume":"43","author":"Albert","year":"2000","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2021121021282400600_B5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2105\/AJPH.75.1.18","article-title":"Industry invites regulation: the passage of the Pure Food and Drug Act of 1906.","volume":"75","author":"Barkan","year":"1985","journal-title":"Am J Public Health"},{"issue":"2","key":"2021121021282400600_B6","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/10550881003684491","article-title":"Women and drug addiction: a historical perspective.","volume":"29","author":"Kandall","year":"2010","journal-title":"J Addict Dis"},{"issue":"1","key":"2021121021282400600_B7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/scientificamerican0791-40","article-title":"Opium, cocaine and marijuana in American history.","volume":"265","author":"Musto","year":"1991","journal-title":"Sci Am"},{"key":"2021121021282400600_B8","unstructured":"Shuster\u2008AM. G.I. heroin addiction epidemic in Vietnam. The New York Times. May 16, 1971. Available at: https:\/\/www.nytimes.com\/1971\/05\/16\/archives\/gi-heroin-addiction-epidemic-in-vietnam-gi-heroin-addiction-is.html. Accessed August 14, 2018"},{"key":"2021121021282400600_B9","unstructured":"Janos\u2008A. G.I. drug use in Vietnam soared\u2014with their commanders\u2019 help. History. April 18, 2018. Available at: https:\/\/www.history.com\/news\/drug-use-in-vietnam. Accessed August 14, 2018"},{"key":"2021121021282400600_B10","unstructured":"Gupta\u2008S. Vietnam, heroin and the lesson of disrupting addiction. CNN. December 22, 2015. Available at: https:\/\/www.cnn.com\/2015\/12\/21\/health\/vietnam-heroin-disrupting-addiction\/index.html. Accessed August 14, 2018"},{"issue":"2","key":"2021121021282400600_B11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/15360288.2012.678473","article-title":"Relieving pain in America: a blueprint for transforming prevention, care, education, and research.","volume":"26","author":"Simon","year":"2012","journal-title":"J Pain Palliat Care Pharmacother"},{"issue":"2","key":"2021121021282400600_B12","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJM198001103020221","article-title":"Addiction rare in patients treated with narcotics.","volume":"302","author":"Porter","year":"1980","journal-title":"N Engl J Med"},{"key":"2021121021282400600_B13","author":"Partnership for a Drug-Free America","year":"2008"},{"key":"2021121021282400600_B14","author":"Guy"},{"key":"2021121021282400600_B15","volume-title":"Treating Drug Problems: Volume 2: Commissioned Papers on Historical, Institutional, and Economic Contexts of Drug Treatment","author":"Besteman","year":"1992"},{"key":"2021121021282400600_B16","volume-title":"Federal Regulation of Methadone Treatment","author":"Rettig","year":"1995"},{"key":"2021121021282400600_B17","first-page":"449","article-title":"Maturation of the adolescent brain.","volume":"9","author":"Arain","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2021121021282400600_B18","first-page":"6","article-title":"Adolescent development of the reward system.","volume":"4","author":"Galvan","year":"2010","journal-title":"Front Hum Neurosci"},{"key":"2021121021282400600_B19","author":"Center for Behavioral Health Statistics and Quality","year":"2014","journal-title":"Results From the 2013 National Survey on Drug Use and Health: Detailed Tables"},{"key":"2021121021282400600_B20","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1196\/annals.1440.010","article-title":"The adolescent brain.","volume":"1124","author":"Casey","year":"2008","journal-title":"Ann N Y Acad Sci"},{"issue":"24","key":"2021121021282400600_B21","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMra0809890","article-title":"Nicotine addiction.","volume":"362","author":"Benowitz","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"2021121021282400600_B22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archpedi.160.7.739","article-title":"Age at drinking onset and alcohol dependence: age at onset, duration, and severity.","volume":"160","author":"Hingson","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"2021121021282400600_B23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.aap.2014.12.015","article-title":"Impact of age at onset of cannabis use on cannabis dependence and driving under the influence in the United States.","volume":"76","author":"Le Strat","year":"2015","journal-title":"Accid Anal Prev"},{"issue":"12","key":"2021121021282400600_B24","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1111\/j.1360-0443.2007.02015.x","article-title":"Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study.","volume":"102","author":"McCabe","year":"2007","journal-title":"Addiction"},{"issue":"6","key":"2021121021282400600_B25","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1542\/peds.2006-2698","article-title":"Children, adolescents, and advertising.","volume":"118","author":"Strasburger","year":"2006","journal-title":"Pediatrics"},{"issue":"5","key":"2021121021282400600_B26","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/01.CHI.0000046832.09750.D8","article-title":"Treating adolescent heroin use.","volume":"42","author":"Hopfer","year":"2003","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021121021282400600_B27","doi-asserted-by":"crossref","DOI":"10.3998\/2027.42\/148123","volume-title":"Monitoring the Future National Survey Results on Drug Use, 1975-2016: Overview, Key Findings on Adolescent Drug Use","author":"Johnston","year":"2018"},{"key":"2021121021282400600_B28","volume-title":"Drug Overdose Deaths Among Adolescents Aged 15\u201319 in the United States: 1999\u20132015. NCHS data brief, no 282","author":"Curtin","year":"2017"},{"issue":"3","key":"2021121021282400600_B29","doi-asserted-by":"crossref","first-page":"e20161893","DOI":"10.1542\/peds.2016-1893","article-title":"Medication-assisted treatment of adolescents with opioid use disorders.","volume":"138","author":"Committee on Substance Use and Prevention","year":"2016","journal-title":"Pediatrics"},{"issue":"17","key":"2021121021282400600_B30","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2008.574","article-title":"Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.","volume":"300","author":"Woody","year":"2008","journal-title":"JAMA"},{"issue":"8","key":"2021121021282400600_B31","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/add.13363","article-title":"A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults.","volume":"111","author":"Marsch","year":"2016","journal-title":"Addiction"},{"key":"2021121021282400600_B32","unstructured":"Substance Abuse and Mental Health Services Administration (SAMHSA). Buprenorphine. Available at: https:\/\/www.samhsa.gov\/medication-assisted-treatment\/treatment\/buprenorphine. Accessed August 15, 2018"},{"issue":"3","key":"2021121021282400600_B33","doi-asserted-by":"crossref","first-page":"ES231","DOI":"10.36076\/ppj.2012\/15\/ES231","article-title":"Office-based opioid dependence treatment.","volume":"15","author":"Colson","year":"2012","journal-title":"Pain Physician"},{"key":"2021121021282400600_B34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2017.04.005","article-title":"Why aren\u2019t physicians prescribing more buprenorphine?","volume":"78","author":"Huhn","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"2021121021282400600_B35","unstructured":"SAMHSA. Medication-assisted treatment: physician and program data. Available at: https:\/\/www.samhsa.gov\/programs-campaigns\/medication-assisted-treatment\/training-materials-resources\/physician-program-data. Accessed August 17, 2018"},{"issue":"10051","key":"2021121021282400600_B36","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/S0140-6736(16)31573-2","article-title":"How the paediatric workforce can address the opioid crisis.","volume":"388","author":"Hadland","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"2021121021282400600_B37","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1001\/jamapediatrics.2017.0745","article-title":"Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014.","volume":"171","author":"Hadland","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"6","key":"2021121021282400600_B38","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jadohealth.2016.12.023","article-title":"Medication-assisted treatment for adolescents in specialty treatment for opioid use disorder.","volume":"60","author":"Feder","year":"2017","journal-title":"J Adolesc Health"},{"issue":"3","key":"2021121021282400600_B39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jsat.2014.04.006","article-title":"Emerging adult age status predicts poor buprenorphine treatment retention.","volume":"47","author":"Schuman-Olivier","year":"2014","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"2021121021282400600_B40","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jamapediatrics.2017.1269","article-title":"Closing the medication-assisted treatment gap for youth with opioid use disorder.","volume":"171","author":"Saloner","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"1","key":"2021121021282400600_B41","doi-asserted-by":"crossref","first-page":"e20161210","DOI":"10.1542\/peds.2016-1210","article-title":"Substance use screening, brief intervention, and referral to treatment.","volume":"138","author":"Committee on Substance Use and Prevention","year":"2016","journal-title":"Pediatrics"},{"key":"2021121021282400600_B42","doi-asserted-by":"crossref","first-page":"j1550","DOI":"10.1136\/bmj.j1550","article-title":"Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies.","volume":"357","author":"Sordo","year":"2017","journal-title":"BMJ"},{"key":"2021121021282400600_B43","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2018.1455165","article-title":"A novel approach to treating adolescents with opioid use disorder in pediatric primary care [published online ahead of print March 29, 2018].","author":"Levy","journal-title":"Subst Abus"},{"issue":"12","key":"2021121021282400600_B44","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.2105\/AJPH.2015.302788","article-title":"Data collection and harmonization in HIV research: the seek, test, treat, and retain initiative at the national institute on drug abuse.","volume":"105","author":"Chandler","year":"2015","journal-title":"Am J Public Health"},{"key":"2021121021282400600_B45","unstructured":"Davis\u2008B; ASAM. ASAM celebrates as addiction medicine is recognized as new medical subspecialty. 2016. Available at: https:\/\/www.asam.org\/resources\/publications\/magazine\/read\/article\/2016\/03\/14\/asam-celebrates-as-addiction-medicine-is-recognized-as-new-medical-subspecialty. Accessed August 15, 2018"},{"key":"2021121021282400600_B46","unstructured":"Debakey\u2008ME, Asghar-Ali\u2008AA, Stanton\u2008LA, Guthrie\u2008TM, Strauss\u2008JB. Addiction psychiatry programs. 2018. Available at: https:\/\/apps.acgme.org\/ads\/Public\/Reports\/ReportRun?ReportId=1&CurrentYear=2018&SpecialtyCode=401&IncludePreAccreditation=false. Accessed August 15, 2018"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-2752\/1076441\/peds_20182752.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2018-2752\/1076441\/peds_20182752.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T02:01:51Z","timestamp":1639188111000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/143\/2\/e20182752\/37310\/Youth-and-the-Opioid-Epidemic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,1]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,2,1]]},"published-print":{"date-parts":[[2019,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2018-2752","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,1]]},"article-number":"e20182752"}}